<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5833069</article-id><article-id pub-id-type="publisher-id">4147</article-id><article-id pub-id-type="doi">10.1186/s12885-018-4147-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>High CD8<sup>+</sup> and absence of Foxp3<sup>+</sup> T lymphocytes infiltration in gallbladder tumors correlate with prolonged patients survival</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Flux&#x000e1;</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Rojas-Sep&#x000fa;lveda</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gleisner</surname><given-names>Mar&#x000ed;a Alejandra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tittarelli</surname><given-names>Andr&#x000e9;s</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Villegas</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tapia</surname><given-names>Loreto</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rivera</surname><given-names>Mar&#x000ed;a Teresa</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez</surname><given-names>Mercedes Natalia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cat&#x000e1;n</surname><given-names>Felipe</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Uribe</surname><given-names>Mario</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Salazar-Onfray</surname><given-names>Flavio</given-names></name><address><phone>+56 2 29786345</phone><email>fsalazar@u.uchile.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 4466</institution-id><institution-id institution-id-type="GRID">grid.443909.3</institution-id><institution>Disciplinary Program of Immunology, Institute of Biomedical Sciences, Faculty of Medicine, </institution><institution>Universidad de Chile, </institution></institution-wrap>8380453 Santiago, Chile </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 4466</institution-id><institution-id institution-id-type="GRID">grid.443909.3</institution-id><institution>Millennium Institute on Immunology and Immunotherapy, Faculty of Medicine, </institution><institution>Universidad de Chile, </institution></institution-wrap>8380453 Santiago, Chile </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.414618.e</institution-id><institution>Unidad de Anatom&#x000ed;a Patol&#x000f3;gica, </institution><institution>Hospital del Salvador, </institution></institution-wrap>7500922 Santiago, Chile </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0385 4466</institution-id><institution-id institution-id-type="GRID">grid.443909.3</institution-id><institution>Departamento de Cirug&#x000ed;a Oriente, Faculty of Medicine, </institution><institution>Universidad de Chile, </institution></institution-wrap>8380453 Santiago, Chile </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>18</volume><elocation-id>243</elocation-id><history><date date-type="received"><day>19</day><month>12</month><year>2016</year></date><date date-type="accepted"><day>19</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Gallbladder cancer (GBC), although infrequent in industrialized countries, has high incidence rates in certain world regions, being a leading cause of death among elderly Chilean women. Surgery is the only effective treatment, and a five-year survival rate of advanced-stage patients is less than 10%. Hence, exploring immunotherapy is relevant, although GBC immunogenicity is poorly understood. This study examined the relationship between the host immune response and GBC patient survival based on the presence of tumor-infiltrating lymphocytes at different disease stages.</p></sec><sec><title>Methods</title><p id="Par2">Tumor tissues from 80 GBC patients were analyzed by immunohistochemistry for the presence of CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and Foxp3<sup>+</sup> T cell populations, and the results were associated with clinical stage and patient survival.</p></sec><sec><title>Results</title><p id="Par3">The majority of tumor samples showed CD3<sup>+</sup> T cell infiltration, which correlated with better prognosis, particularly in advanced disease stages. CD8<sup>+</sup>, but not CD4<sup>+</sup>, T cell infiltration correlated with improved survival, particularly in advanced disease stages. Interestingly, a&#x02009;&#x0003c;&#x02009;1 CD4<sup>+</sup>/CD8<sup>+</sup> T cell ratio was related with increased survival. Additionally, the presence of Foxp3<sup>+</sup> T cells correlated with decreased patient survival, whereas a&#x02009;&#x02264;&#x02009;1 Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratio was associated with improved patient survival.</p></sec><sec><title>Conclusions</title><p id="Par4">Depending on the disease stage, the presence of CD8<sup>+</sup> and absence of Foxp3<sup>+</sup> T cell populations in tumor tissues correlated with improved GBC patient survival, and thus represent potential markers for prognosis and management of advanced disease, and supports testing of immunotherapy.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12885-018-4147-6) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gallbladder cancer</kwd><kwd>Tumor infiltrating lymphocytes</kwd><kwd>Patient survival</kwd><kwd>CD8<sup>+</sup> T cells</kwd><kwd>Foxp3<sup>+</sup> T cells</kwd></kwd-group><funding-group><award-group><funding-source><institution>Fondecyt</institution></funding-source><award-id>1171213</award-id><award-id>11160380</award-id><principal-award-recipient><name><surname>Tittarelli</surname><given-names>Andr&#x000e9;s</given-names></name><name><surname>Salazar-Onfray</surname><given-names>Flavio</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Fondef</institution></funding-source><award-id>ID16i10148</award-id><principal-award-recipient><name><surname>Salazar-Onfray</surname><given-names>Flavio</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>MIII</institution></funding-source><award-id>P09/016-F</award-id><principal-award-recipient><name><surname>Salazar-Onfray</surname><given-names>Flavio</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>(CONICYT)-PCHA/Doctorado Nacional</institution></funding-source><award-id>21130465</award-id></award-group><award-group><funding-source><institution>CONICYT-PAI/TESIS DOCTORADO SECTOR PRODUCTIVO</institution></funding-source><award-id>7815110008</award-id></award-group><award-group><funding-source><institution>FONDECYT POSTDOCTORADO </institution></funding-source><award-id>3170917</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Gallbladder cancer (GBC) is the most common cancer of the biliary tree. Although GBC is infrequent in developed countries [<xref ref-type="bibr" rid="CR1">1</xref>], in South America this tumor constitutes a major health problem [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In particular, Chile has the highest incidence and mortality rates of GBC in the world, being this cancer the leading cause of neoplastic disease-related deaths in women (12.8 cases per 100,000) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. The underlying causes for the high risk of GBC in Chile are unclear, but several important risk factors likely contribute, including chronic inflammation caused by gallstones, high obesity rates, and genetic susceptibility in women of indigenous <italic>Mapuche</italic> ancestry, in which the incidence rise up to 27.3 cases per 100,000 [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par22">The most effective GBC treatment is surgical removal of the primary tumor and areas of local extension. Unfortunately, less than 10% of the patients have resectable tumors, and nearly 50% of them present metastasis at the time of diagnosis [<xref ref-type="bibr" rid="CR6">6</xref>]. In fact, even after surgery, most GBC-patients progress to a metastatic stage, stressing the need for novel adjuvant therapies, such as immunotherapy. Recently, we reported that dendritic cell (DC)-immunization could improve long-term survival in melanoma and prostate cancer patients [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. A way to determine the potential usefulness of DC-based immunotherapy in GBC patients is to explore the immunogenicity of GBC tumors by measuring the impact of T cell subpopulation infiltration at tumor sites and correlate it with overall patient survival.</p><p id="Par23">The presence of tumor-infiltrating lymphocytes (TILs) in cancer tissues is indicative of an active host immune response against cancer cells. CD4<sup>+</sup> and CD8<sup>+</sup> T cells are the main components of tumor-specific, cellular adaptive immunity. Indeed, several studies have shown that a high presence of tumor-infiltrating CD8<sup>+</sup> T cells is associated with favorable prognosis in colorectal, ovarian, breast, pancreatic, and biliary tract cancers (BTC) [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. However, this is not a general principle that can be applied to all kinds of tumors [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par24">CD4<sup>+</sup> T cells are also essential for regulating immune responses, a role exercised mainly through the secretion of different cytokines [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. During the activation of T cell receptors in a local cytokine milieu, CD4<sup>+</sup> T cells can differentiate into several lineages of effector T cells or regulatory T cells (Tregs), as defined by cytokine expression and cell function patterns. Tregs can inhibit effector T cell functions in physiological and illness states through cell-cell contact or by the secretion of regulatory cytokines, such as IL-10 and TGF-&#x003b2; [<xref ref-type="bibr" rid="CR19">19</xref>]. Foxp3 is a transcription factor and a Treg-specific marker that regulates Treg development [<xref ref-type="bibr" rid="CR20">20</xref>]. Considering that Tregs within the tumor microenvironment might significantly suppress local antitumor immune responses [<xref ref-type="bibr" rid="CR21">21</xref>], increased presence of Foxp3<sup>+</sup> T cells in peripheral blood or tumor tissues have been associated with negative prognoses for various cancers [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR24">24</xref>]. In BTC, sub-populations of infiltrating immune cells have so far only been studied in parts, using relatively small and heterogeneous patient cohorts, and without a defined disease stage analysis [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par25">The purpose of this study was to evaluate the prognostic significance of various TIL subtypes, including CD4<sup>+</sup>, CD8<sup>+</sup>, and Foxp3<sup>+</sup> T cells, and to analyze the influence of density and distribution of tumor-infiltrating immune cell populations at different stages of the disease, in a homogeneous cohort of Chilean GBC patients with a long term follow up. Our results suggest that the balance between CD8<sup>+</sup> and Foxp3<sup>+</sup> cells in the tumor microenvironment acts as a predictor for GBC patient survival, a situation that allows speculating that boosting natural antitumor immune responses through immunotherapy could represent a possible adjuvant treatment for GBC patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients</title><p id="Par26">Between 1996 and 2004, resected tumor samples were obtained from 64 female and 16 male GBC patients (80 patients total) treated at the Hospital del Salvador (Santiago, Chile). The stage of GBC was assigned according to the TNM Classification of Malignant Tumors (7th edition, 2010). Patients were selected on the basis of suitable paraffin-embedded tissue, as well as the availability of a complete clinical-pathology and follow-up data. All patients included in the study died due to GBC. The cause of death was verified in the database of the national civil registry.</p><p id="Par27">Patients were classified by disease stage as either early stage (stages 0, I; pTNM Is, Ia and Ib) or advanced stage (stages II, III and IV). The early GBC stage patients were defined by the presence of adenocarcinoma confined to the tunica muscularis (Tis, T1a, or T1b) according the AJCC/UICC, TNM Classification 2010. The study was performed in agreement with the Helsinki Declaration and approved by the Bioethical Committee for Human Research of the Faculty of Medicine, University of Chile (ID number: 078&#x02013;2008). All patients signed a letter of informed consent at the time of surgery (For patient characteristics please refer to Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Age range</th><th>Indian American<break/>Ethnicity<sup>a</sup></th><th>pTNM</th><th>Stage</th><th>Histological differentiation</th><th>Survival (Months)</th><th>Adjuvant Treatment</th><th>CD3</th><th>CD4</th><th>CD8</th><th>FoxP3</th></tr></thead><tbody><tr><td>1</td><td char="/" align="char">30/79</td><td>No</td><td>TisN0M0</td><td>0</td><td>In Situ</td><td>60</td><td>No</td><td>5</td><td>7</td><td>8</td><td>0</td></tr><tr><td>2</td><td/><td>ND</td><td>TisN0M0</td><td>0</td><td>In Situ</td><td>48</td><td>No</td><td>36</td><td>24</td><td>16</td><td>8</td></tr><tr><td>3</td><td rowspan="2"/><td>No</td><td>TisN0M0</td><td>0</td><td>In Situ</td><td>60</td><td>No</td><td>34</td><td>23</td><td>22</td><td>4</td></tr><tr><td>4</td><td>Yes</td><td>TisN0M0</td><td>0</td><td>In Situ</td><td>60</td><td>No</td><td>20</td><td>16</td><td>1</td><td>5</td></tr><tr><td>17</td><td/><td>No</td><td>TisN0M0</td><td>0</td><td>In Situ</td><td>60</td><td>No</td><td>46</td><td>39</td><td>18</td><td>2</td></tr><tr><td>6</td><td/><td>ND</td><td>T1bN0M0</td><td>I</td><td>Moderate</td><td>18</td><td>No</td><td>38</td><td>27</td><td>12</td><td>2</td></tr><tr><td>7</td><td/><td>No</td><td>T1bN0M0</td><td>I</td><td>Well</td><td>60</td><td>No</td><td>2</td><td>2</td><td>2</td><td>0</td></tr><tr><td>8</td><td/><td>No</td><td>T1aN0M0</td><td>I</td><td>Well</td><td>60</td><td>No</td><td>14</td><td>21</td><td>46</td><td>2</td></tr><tr><td>9</td><td/><td>ND</td><td>T1bN0M0</td><td>I</td><td>Well</td><td>3</td><td>No</td><td>22</td><td>17</td><td>20</td><td>1</td></tr><tr><td>10</td><td/><td>ND</td><td>T1aN0M0</td><td>I</td><td>Well</td><td>60</td><td>No</td><td>32</td><td>24</td><td>19</td><td>2</td></tr><tr><td>11</td><td/><td>No</td><td>T1bN0M0</td><td>I</td><td>Well</td><td>60</td><td>No</td><td>36</td><td>16</td><td>32</td><td>0</td></tr><tr><td>12</td><td/><td>No</td><td>T1bN0M0</td><td>I</td><td>Poorly</td><td>60</td><td>No</td><td>28</td><td>22</td><td>19</td><td>0</td></tr><tr><td>13</td><td/><td>No</td><td>T1aN0M0</td><td>I</td><td>Well</td><td>60</td><td>No</td><td>14</td><td>18</td><td>10</td><td>0</td></tr><tr><td>14</td><td/><td>No</td><td>T1aN0M0</td><td>I</td><td>Moderate</td><td>60</td><td>No</td><td>20</td><td>18</td><td>23</td><td>0</td></tr><tr><td>15</td><td/><td>No</td><td>T1bN0M0</td><td>I</td><td>Moderate</td><td>60</td><td>No</td><td>15</td><td>14</td><td>22</td><td>0</td></tr><tr><td>16</td><td/><td>No</td><td>T1bN0M0</td><td>I</td><td>Well</td><td>29</td><td>CT&#x02009;+&#x02009;RT</td><td>16</td><td>12</td><td>10</td><td>8</td></tr><tr><td>18</td><td/><td>Yes</td><td>T1bN0M0</td><td>I</td><td>Moderate</td><td>60</td><td>No</td><td>28</td><td>14</td><td>27</td><td>0</td></tr><tr><td>19</td><td/><td>No</td><td>T1bN0M0</td><td>I</td><td>Well</td><td>60</td><td>CT&#x02009;+&#x02009;RT</td><td>42</td><td>26</td><td>26</td><td>17</td></tr><tr><td>20</td><td/><td>Yes</td><td>T1bN0M0</td><td>I</td><td>Moderate</td><td>0</td><td>No</td><td>15</td><td>8</td><td>0</td><td>9</td></tr><tr><td>21</td><td char="/" align="char">38/85</td><td>No</td><td>T2N0M0</td><td>II</td><td>Poorly</td><td>0</td><td>No</td><td>12</td><td>1</td><td>14</td><td>3</td></tr><tr><td>22</td><td/><td>No</td><td>T2N0M0</td><td>II</td><td>Moderate</td><td>60</td><td>ND</td><td>26</td><td>15</td><td>24</td><td>0</td></tr><tr><td>23</td><td/><td>No</td><td>T2N0M0</td><td>II</td><td>Well</td><td>60</td><td>ND</td><td>21</td><td>15</td><td>38</td><td>5</td></tr><tr><td>24</td><td/><td>N.D</td><td>T2N0M0</td><td>II</td><td>Moderate</td><td>13</td><td>ND</td><td>13</td><td>11</td><td>2</td><td>2</td></tr><tr><td>25</td><td/><td>ND</td><td>T2N0M0</td><td>II</td><td>Moderate</td><td>22</td><td>ND</td><td>18</td><td>14</td><td>11</td><td>6</td></tr><tr><td>26</td><td/><td>No</td><td>T2N0M0</td><td>II</td><td>Moderate</td><td>6</td><td>ND</td><td>24</td><td>31</td><td>2</td><td>1</td></tr><tr><td>27</td><td/><td>No</td><td>T2N0M0</td><td>II</td><td>Moderate</td><td>60</td><td>CT&#x02009;+&#x02009;RT</td><td>22</td><td>23</td><td>17</td><td>3</td></tr><tr><td>28</td><td/><td>No</td><td>T2N0M0</td><td>II</td><td>Moderate</td><td>0</td><td>No</td><td>19</td><td>18</td><td>14</td><td>7</td></tr><tr><td>29</td><td/><td>No</td><td>T2N0M0</td><td>II</td><td>Poorly</td><td>7</td><td>ND</td><td>13</td><td>13</td><td>3</td><td>0</td></tr><tr><td>30</td><td/><td>Yes</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>3</td><td>No</td><td>18</td><td>7</td><td>8</td><td>0</td></tr><tr><td>31</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>60</td><td>No</td><td>34</td><td>4</td><td>25</td><td>0</td></tr><tr><td>32</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Well</td><td>19</td><td>ND</td><td>23</td><td>17</td><td>34</td><td>1</td></tr><tr><td>33</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>4</td><td>No</td><td>80</td><td>70</td><td>38</td><td>5</td></tr><tr><td>34</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>8</td><td>No</td><td>21</td><td>22</td><td>8</td><td>1</td></tr><tr><td>35</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Well</td><td>60</td><td>ND</td><td>24</td><td>25</td><td>7</td><td>0</td></tr><tr><td>36</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>11</td><td>No</td><td>27</td><td>11</td><td>22</td><td>1</td></tr><tr><td>37</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>3</td><td>No</td><td>45</td><td>20</td><td>6</td><td>1</td></tr><tr><td>38</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>2</td><td>No</td><td>16</td><td>20</td><td>5</td><td>9</td></tr><tr><td>39</td><td/><td>ND</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>60</td><td>ND</td><td>36</td><td>10</td><td>31</td><td>20</td></tr><tr><td>40</td><td/><td>ND</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>6</td><td>ND</td><td>ND</td><td>32</td><td>ND</td><td>ND</td></tr><tr><td>41</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>4</td><td>No</td><td>18</td><td>23</td><td>21</td><td>5</td></tr><tr><td>42</td><td/><td>ND</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>4</td><td>ND</td><td>22</td><td>10</td><td>16</td><td>13</td></tr><tr><td>43</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>60</td><td>CT</td><td>12</td><td>13</td><td>26</td><td>7</td></tr><tr><td>44</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>0</td><td>No</td><td>10</td><td>12</td><td>8</td><td>2</td></tr><tr><td>45</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Well</td><td>0</td><td>No</td><td>16</td><td>14</td><td>3</td><td>8</td></tr><tr><td>46</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>5</td><td>ND</td><td>39</td><td>30</td><td>32</td><td>4</td></tr><tr><td>47</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>3</td><td>No</td><td>15</td><td>5</td><td>4</td><td>3</td></tr><tr><td>48</td><td/><td>ND</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>4</td><td>ND</td><td>10</td><td>11</td><td>18</td><td>0</td></tr><tr><td>49</td><td/><td>ND</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>6</td><td>ND</td><td>25</td><td>25</td><td>19</td><td>10</td></tr><tr><td>50</td><td/><td>Yes</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>11</td><td>ND</td><td>26</td><td>15</td><td>7</td><td>0</td></tr><tr><td>51</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>9</td><td>ND</td><td>22</td><td>19</td><td>9</td><td>3</td></tr><tr><td>52</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>1</td><td>No</td><td>5</td><td>6</td><td>8</td><td>0</td></tr><tr><td>53</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>2</td><td>No</td><td>11</td><td>9</td><td>12</td><td>6</td></tr><tr><td>54</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>5</td><td>ND</td><td>37</td><td>17</td><td>30</td><td>0</td></tr><tr><td>55</td><td/><td>ND</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>4</td><td>ND</td><td>12</td><td>12</td><td>21</td><td>7</td></tr><tr><td>56</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Poorly</td><td>1</td><td>No</td><td>37</td><td>42</td><td>0</td><td>1</td></tr><tr><td>57</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>2</td><td>No</td><td>14</td><td>10</td><td>0</td><td>6</td></tr><tr><td>58</td><td/><td>No</td><td>T3N0M0</td><td>IIIA</td><td>Moderate</td><td>4</td><td>No</td><td>10</td><td>7</td><td>0</td><td>1</td></tr><tr><td>59</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Moderate</td><td>60</td><td>ND</td><td>37</td><td>15</td><td>54</td><td>11</td></tr><tr><td>60</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Poorly</td><td>60</td><td>CT&#x02009;+&#x02009;RT</td><td>17</td><td>6</td><td>25</td><td>1</td></tr><tr><td>61</td><td/><td>ND</td><td>T3N1M0</td><td>IIIB</td><td>Poorly</td><td>5</td><td>ND</td><td>28</td><td>20</td><td>17</td><td>4</td></tr><tr><td>62</td><td/><td>ND</td><td>T3N1M0</td><td>IIIB</td><td>Moderate</td><td>16</td><td>ND</td><td>15</td><td>14</td><td>19</td><td>1</td></tr><tr><td>63</td><td/><td>No</td><td>T3N1M0</td><td>IIIB</td><td>Moderate</td><td>5</td><td>No</td><td>32</td><td>19</td><td>27</td><td>15</td></tr><tr><td>64</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Well</td><td>60</td><td>CT&#x02009;+&#x02009;RT</td><td>40</td><td>31</td><td>36</td><td>2</td></tr><tr><td>65</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Moderate</td><td>7</td><td>ND</td><td>21</td><td>19</td><td>10</td><td>1</td></tr><tr><td>66</td><td/><td>ND</td><td>T3N1M0</td><td>IIIB</td><td>Poorly</td><td>5</td><td>No</td><td>20</td><td>17</td><td>26</td><td>26</td></tr><tr><td>67</td><td/><td>Yes</td><td>T2N1M0</td><td>IIIB</td><td>Poorly</td><td>60</td><td>ND</td><td>30</td><td>18</td><td>30</td><td>0</td></tr><tr><td>68</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Moderate</td><td>10</td><td>CT&#x02009;+&#x02009;RT</td><td>19</td><td>14</td><td>17</td><td>7</td></tr><tr><td>69</td><td/><td>ND</td><td>T3N1M0</td><td>IIIB</td><td>Poorly</td><td>11</td><td>CT&#x02009;+&#x02009;RT</td><td>28</td><td>31</td><td>32</td><td>10</td></tr><tr><td>70</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Moderate</td><td>60</td><td>CT&#x02009;+&#x02009;RT</td><td>23</td><td>21</td><td>33</td><td>5</td></tr><tr><td>71</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Moderate</td><td>51</td><td>ND</td><td>23</td><td>12</td><td>13</td><td>1</td></tr><tr><td>72</td><td/><td>ND</td><td>T3N1M0</td><td>IIIB</td><td>Poorly</td><td>2</td><td>No</td><td>33</td><td>8</td><td>16</td><td>0</td></tr><tr><td>73</td><td/><td>No</td><td>T3N1M0</td><td>IIIB</td><td>Moderate</td><td>12</td><td>ND</td><td>11</td><td>14</td><td>17</td><td>10</td></tr><tr><td>74</td><td/><td>No</td><td>T2N1M0</td><td>IIIB</td><td>Poorly</td><td>60</td><td>CT&#x02009;+&#x02009;RT</td><td>23</td><td>13</td><td>10</td><td>2</td></tr><tr><td>75</td><td/><td>No</td><td>T4N1M0</td><td>IVA</td><td>Poorly</td><td>3</td><td>No</td><td>45</td><td>40</td><td>12</td><td>3</td></tr><tr><td>76</td><td/><td>No</td><td>T4N0M0</td><td>IVA</td><td>Moderate</td><td>9</td><td>ND</td><td>20</td><td>26</td><td>8</td><td>ND</td></tr><tr><td>77</td><td/><td>No</td><td>T3N2M0</td><td>IVB</td><td>Moderate</td><td>34</td><td>CT&#x02009;+&#x02009;RT</td><td>13</td><td>16</td><td>19</td><td>0</td></tr><tr><td>78</td><td/><td>No</td><td>T3N2M0</td><td>IVB</td><td>Moderate</td><td>14</td><td>ND</td><td>27</td><td>18</td><td>0</td><td>1</td></tr><tr><td>79</td><td/><td>No</td><td>T3N2M0</td><td>IVB</td><td>Poorly</td><td>9</td><td>ND</td><td>51</td><td>44</td><td>34</td><td>5</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup><italic>Mapuche</italic> ethnical origin was assessed by correlation with patient parents last, family, or middle name</p><p><italic>ND</italic> No Data, <italic>CT</italic> Chemotherapy, <italic>RT</italic> Radiotherapy. White&#x02009;=&#x02009;early stage of disease. Light grey&#x02009;=&#x02009;Late stage of disease</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Immunohistochemistry</title><p id="Par28">Tissue specimens were fixed in 10% formalin and embedded in paraffin wax. Representative blocks, which included the greatest dimensions of the tumor sections, were selected for immunohistochemistry analysis using the streptavidin-biotin-peroxidase method. Paraffin blocks were dissected into 3&#x000a0;&#x003bc;m thick slides, mounted on silanized slides, and subsequently dewaxed and rehydrated using xylene and graded ethanol washes, followed by washing with phosphate-buffered saline (pH&#x000a0;7.4). The heat-induced epitope retrieval protocol, with 20&#x000a0;min heating and 30&#x000a0;min cooling, was used to retrieve antigens. The slides were placed on a retrieval solution (Tris-EDTA, pH&#x000a0;9.0) or citrate buffer (pH&#x000a0;6.0) depending on each antibody. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide for 30&#x000a0;min followed by Tris-buffered saline washing. A protein block solution was applied for 45&#x000a0;min to stop non-specific antibody binding. The following primary antibodies were used according to the manufacturers&#x02019; instructions: monoclonal rabbit IgG anti-CD3, clone SP7 (1:250 dilution; Thermo Scientific); monoclonal rabbit IgG anti-CD4, clone SP35 (1:25 dilution; BioSB); monoclonal mouse IgG anti-CD8, clone C8/144B (1:50 dilution; DAKO); and monoclonal mouse IgG anti-Foxp3, clone 236A/E7 (1:50 dilution; Abcam).</p><p id="Par29">The slides were incubated with the primary antibodies in moist chambers for 45&#x000a0;min at room temperature. Then, the slides were washed with three changes of Tris-buffered saline before incubation with labeled polymer horseradish peroxidase secondary antibodies for an additional 45&#x000a0;min at room temperature (Universal Secondary Antibody, ABC Vectastain Kit Elite PK6200, Vector Laboratories). Slides were subsequently incubated with the ABC solution for 30&#x000a0;min (ABC Vectastain Kit Elite PK6200, Vector Laboratories), washed with three changes of Tris-buffered saline, incubated with DAB (3,3&#x02032;-diaminobenzidine tetrahydrochloride)-Chromogen solution (DAKO) according to manufacturer&#x02019;s instructions, and washed with deionized water. Background staining was performed with Mayer&#x02019;s haematoxylin solution. Finally, the sections were dehydrated through ascending alcohols and xylene and then mounted. Negative control slides omitting the primary antibody were included in all batches. Sections from tonsil tissue were used as positive controls for CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> cell detections.</p><p id="Par30">Because of limited access to material, one patient sample was not analyzed for CD8<sup>+</sup> and CD4<sup>+</sup> T cell infiltration, as well as two patients samples were excluded for FoxP3<sup>+</sup> T cell infiltration analysis.</p></sec><sec id="Sec5"><title>Quantification methods</title><p id="Par31">Two pathologists independently scored positive for stained TILs. CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and Foxp3<sup>+</sup>. TILs were counted using an optical microscope (40X, Olympus Bx40F-3) in five randomly selected high power fields. The cell count average was calculated, and these values were used as the final cells/field assigned to each patient.</p><p id="Par32">Sturges&#x02019; Rule was used to establish categories, which were compared with one another to obtain the cut-off values for defining high and low infiltration levels. The cut-off values for each cell subtype were as follows: 23 cells/field for CD3<sup>+</sup>, 22 cells/field for CD8<sup>+</sup>, and 20 cells/field for CD4<sup>+</sup> cells. Foxp3<sup>+</sup> cell infiltration was analyzed as positive or negative since the different categories showed no differences. Furthermore, since the intraepithelial and peritumoral infiltration levels showed no differences in relation to patient survival, both compartments were analyzed together.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par33">Statistical analyses were performed using GraphPad Prism (version 5.0, GraphPad Software Incorporated). Comparisons between groups were examined by one-way analysis of variance. Overall survival was calculated according to the Kaplan-Meier method. The log-rank test was used to compare survival rates between patient subgroups based on the status of either high or low immune cell infiltration. Cox&#x02019;s proportional hazards model was used for univariate analysis of cell infiltration and overall survival, with analysis performed using the Stata statistical software (version 12.1, StataCorp). Probability (<italic>p</italic>) values &#x0003c;&#x02009;0.05 were considered significant in all analyses.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient characteristics and infiltrating T cell numbers</title><p id="Par34">The cause of death for all patients was GBC, according to databases of the national civil registry. All cases of cancer evaluated in this study were diagnosed as adenocarcinoma of the gallbladder (<italic>n</italic>&#x02009;=&#x02009;79). Only one patient was excluded from the statistic study because the histopathological analysis of the biopsy diagnosed a carcinoid of the gallbladder. For all remaining 79 patients with GBC, pathological data was acquired on TNM classification, differentiation, vessel involvement, lymphatic involvement, perineural involvement, and stage grouping. Follow-up and clinical data were also obtained from all patients. Information regarding basic clinical-pathology characteristics, treatment and overall patient survival time is summarized in Table <xref rid="Tab1" ref-type="table">1</xref>, and Additional&#x000a0;file&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>: Figure S1.</p><p id="Par35">Representative immunohistochemistry images for CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and Foxp3<sup>+</sup> T cell infiltrations in GBC samples are provided in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>. All patient samples (<italic>n</italic>&#x02009;=&#x02009;79) showed immune cell infiltration in the peritumoral and intratumoral compartments. When the immune cells infiltrating each compartment were independently quantified, no statistical associations with overall GBC patient survival were found (data not shown). Distributional analysis by photomicrograph field for all immune cell infiltrate quantities revealed that only the number of CD4<sup>+</sup> TILs evidenced Gaussian distribution (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). Additionally, total counts of CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and Foxp3<sup>+</sup> T cells were similar in all GBC samples, regardless of the disease stage (Fig. <xref rid="Fig1" ref-type="fig">1c</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Immune cell infiltration in gallbladder cancer. <bold>a</bold> Representative photomicrographs of immunohistochemical staining T cells (CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>+</sup>, and Foxp3<sup>+</sup>) within GBC tissues (scale bar, 40&#x000a0;&#x003bc;m). <bold>b</bold> Quantified distribution of immune cell infiltration by photomicrograph field in GBC tissues. The frequency is displayed as the number of cases. The superimposed black lines show the fitted Gaussian distribution. Gaussian distribution was only found on CD4<sup>+</sup> T cells (goodness of fit: R<sup>2</sup>&#x02009;=&#x02009;0.796). <bold>c</bold> Quantified distribution of immune cell infiltration in GBC tissues according to GBC stage. Data represent the mean&#x02009;&#x000b1;&#x02009;SD</p></caption><graphic xlink:href="12885_2018_4147_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec9"><title>CD3<sup>+</sup> T cell infiltration correlates with increased survival of advanced stage gallbladder cancer patients</title><p id="Par36">The GBC tumor tissues were grouped into two categories, according to the degree of CD3<sup>+</sup>, CD4<sup>+</sup>, or CD8<sup>+</sup> T cell infiltration and either high or low infiltration rate. Out of 79 patients with positive CD3<sup>+</sup> T cell tumor infiltration, 42 (53.8%) were classified as low CD3<sup>+</sup> infiltration rate and 36 (46.2%) as high. The median survival time of GBC patients with low and high CD3<sup>+</sup> infiltration rates were 8.37 and 33.3&#x000a0;months (<italic>p</italic>&#x02009;=&#x02009;0.06), respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). Early (stage 0 and I) and advanced stage (II, III and IV) patients were separately grouped and analyzed. There was no significant difference in median survival time between low and high CD3<sup>+</sup> infiltration (<italic>p</italic>&#x02009;=&#x02009;0.63) in the early stage patients (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). However, higher infiltration by CD3<sup>+</sup> T cells was correlated with better median survival time (10.6&#x000a0;months vs. 4.6&#x000a0;months, respectively; <italic>p</italic>&#x02009;=&#x02009;0.02; HR&#x02009;=&#x02009;1.96; CI&#x02009;=&#x02009;1.054&#x02013;3.445) in advanced stage patients (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Increased CD3<sup>+</sup> T cell infiltration in gallbladder cancer tissues correlates with improved late stage patient survival. Kaplan-Meier survival curves for patients with high and low CD3<sup>+</sup> T cells infiltration in primary tumors based on Sturges&#x02019; Rule: (<bold>a</bold>) All stages; (<bold>b</bold>) Early stages (0 and I); and (<bold>c</bold>) Advanced stages (II, IIIA, IIIB, and IV). High CD3<sup>+</sup> T cell infiltration was significantly associated with prolonged survival in advanced stage patients (log-rank <italic>p</italic>&#x02009;=&#x02009;0.03). The survival proportions of patients after GBC diagnosis in a 5-year term are shown to the right of the curves</p></caption><graphic xlink:href="12885_2018_4147_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec10"><title>High CD8<sup>+</sup> T cell infiltration correlates with increased survival of gallbladder cancer patients</title><p id="Par37">Similarly, 78 patient samples were grouped by high or low CD8<sup>+</sup> T cell infiltration. Patients with higher CD8<sup>+</sup> T cell infiltration had greater median survival times than patients with low CD8<sup>+</sup> T cell infiltration, undefined (62.5% of patients still survive) vs. 8.7&#x000a0;months, respectively (<italic>p</italic>&#x02009;=&#x02009;0.002; HR&#x02009;=&#x02009;2.44; CI&#x02009;=&#x02009;1.38&#x02013;4.3) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). When CD8<sup>+</sup> T cell infiltration was assessed within early and advanced patient groups, high CD8<sup>+</sup> T cell infiltration was associated with better prognosis than low CD8<sup>+</sup> T cell infiltration for the early stage group. None of the early stage GBC patients from the high CD8<sup>+</sup> T cell infiltration group died during the study, whereas 33.4% of the patients with low CD8<sup>+</sup> T cell infiltration died during the follow-up period (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). Remarkably, high CD8<sup>+</sup> T cell infiltration in advanced stage patients was correlated with a greater median survival time compared to low CD8<sup>+</sup> T cell infiltration, undefined (52.6% of patients survive) vs. 5.2&#x000a0;months, respectively (<italic>p</italic>&#x02009;=&#x02009;0.0004; HR&#x02009;=&#x02009;2.89; CI&#x02009;=&#x02009;1.6&#x02013;5.22) (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Increased CD8<sup>+</sup> T cell infiltration in gallbladder cancer tissues correlates with improved patient survival. Kaplan-Meier survival curves for patients with high and low CD8<sup>+</sup> T cell infiltration in primary tumors based on Sturges&#x02019; Rule: (<bold>a</bold>) All stages; (<bold>b</bold>) Early stages (0 and I); and (<bold>c</bold>) Advanced stages (II, IIIA, IIIB, and IV). High CD8<sup>+</sup> T cell infiltration was significantly associated with prolonged survival particularly in advanced stage patients (log-rank <italic>p</italic>&#x02009;=&#x02009;0.0004). The survival proportions of patients after GBC diagnosis in a 5-year term are shown to the right of the curves</p></caption><graphic xlink:href="12885_2018_4147_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec11"><title>CD4<sup>+</sup> T cell infiltration was not associated with the overall survival of gallbladder cancer patients</title><p id="Par38">In 78 analyzed samples, CD4<sup>+</sup> T cells were found in both peri and intratumoral compartments with no relationship between distribution and stage of the disease. Additionally, when early GBC and advanced stage patients were analyzed separately, no differences in survival time were observed between high and low CD4<sup>+</sup> T cell infiltration groups (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S2).</p></sec><sec id="Sec12"><title>Foxp3<sup>+</sup> T cell infiltration was rare, but associated with reduced survival of gallbladder cancer patients</title><p id="Par39">Assessed GBC tumor samples (<italic>n</italic>&#x02009;=&#x02009;77) were poorly infiltrated by Foxp3<sup>+</sup> T cells (Fig. <xref rid="Fig1" ref-type="fig">1b and c</xref>). Specifically, 20 samples were negative for Foxp3<sup>+</sup> T cells and 57 were positive. Patients with negative Foxp3<sup>+</sup> T cell infiltration had a better survival outcome than patients with positive infiltration (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>). Indeed, while patients from the positive Foxp3<sup>+</sup> T cell infiltration group showed a median survival of 10.4&#x000a0;months, 60% of patients with negative Foxp3<sup>+</sup> T cell infiltration survived the 5-year follow-up period (<italic>p</italic>&#x02009;=&#x02009;0.03; HR&#x02009;=&#x02009;0.5; CI&#x02009;=&#x02009;0.27&#x02013;0.9) (Fig. <xref rid="Fig4" ref-type="fig">4a</xref>). The same association was observed when early stage patients were analyzed separately from those in the advanced stage. All early stage GBC patients with negative Foxp3<sup>+</sup> T cell infiltration survived the 5-year follow-up period whereas only 58.3% of early stage patients with positive infiltration of Foxp3<sup>+</sup> T cells survived (<italic>p</italic>&#x02009;=&#x02009;0.04; HR&#x02009;=&#x02009;0.16; CI&#x02009;=&#x02009;0.02&#x02013;0.95) (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>). On the other hand, the absence of Foxp3<sup>+</sup> T cells was not associated with better prognosis in advanced stage patients (Fig. <xref rid="Fig4" ref-type="fig">4c</xref>).<fig id="Fig4"><label>Fig. 4</label><caption><p>Increased Foxp3<sup>+</sup> T cell infiltration in gallbladder cancer tissues correlates with poor patient survival. Kaplan-Meier survival curves for patients with positive or negative Foxp3<sup>+</sup> T cell infiltration in primary tumors for (<bold>a</bold>) All stages; (<bold>b</bold>) Early stages (0 and I); and (<bold>c</bold>) Advanced stages (II, IIIA, IIIB, and IV). Negative Foxp3<sup>+</sup> T cell infiltration was significantly associated with prolonged survival in all stages and early stage patients (log-rank <italic>p</italic>&#x000a0;=&#x02009;0.03 and 0.04, respectively). The survival proportions of patients after GBC diagnosis in a 5-year term are shown to the right of the curves</p></caption><graphic xlink:href="12885_2018_4147_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec13"><title>Lower CD4<sup>+</sup>/CD8<sup>+</sup> and Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratios in gallbladder cancer tissues correlates with improved patient survival</title><p id="Par40">Typically, variations in the proportion of different tumor-infiltrating immune cells are more accurate than absolute numbers for estimating the immune microenvironment [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Therefore, CD4<sup>+</sup>/CD8<sup>+</sup> T cell ratios were used to study influence of cell infiltration on the GBC patient survival. No statistical differences were found in overall survival when comparing patients with a&#x02009;&#x02264;&#x02009;1 ratio to those with a&#x02009;&#x0003e;&#x02009;1 ratio (<italic>p</italic>&#x02009;=&#x02009;0.06; Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5a</xref>). A similar situation was found when early stage patients were separately analyzed (<italic>p</italic>&#x02009;=&#x02009;0.22; Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). However, the analysis of advanced stage patients showed that a&#x02009;&#x02264;&#x02009;1 CD4<sup>+</sup>/CD8<sup>+</sup> T cell ratio correlated with improved patient median survival (11.8&#x000a0;months vs. 5.9&#x000a0;months, <italic>p</italic>&#x02009;=&#x02009;0.01) (Fig. <xref rid="Fig5" ref-type="fig">5c</xref>.)<fig id="Fig5"><label>Fig. 5</label><caption><p>Lower CD4<sup>+</sup>/CD8<sup>+</sup> and Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratios in gallbladder cancer tissues correlates with improved patient survival. Kaplan-Meier survival curves for patients by (<bold>a</bold>-<bold>c</bold>) CD4<sup>+</sup>/CD8<sup>+</sup> T cell ratio or (<bold>d</bold>) Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratio in primary tumors for (<bold>a</bold>, <bold>d</bold>) All stages; (<bold>b</bold>) Early stages (0 and I); and (<bold>c</bold>) Advanced stages (II, IIIA, IIIB, and IV). A&#x02009;&#x02264;&#x02009;1 CD4<sup>+</sup>/CD8<sup>+</sup> T cell ratio was significantly associated with prolonged survival in advanced stage patients (log-rank <italic>p</italic>&#x000a0;=&#x02009;0.01). A&#x000a0;&#x02264;&#x000a0;1 Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratio was significantly associated with prolonged survival in all stages patients (log-rank <italic>p</italic>&#x000a0;=&#x02009;0.002). The survival proportions of patients after GBC diagnosis in a 5-year term are shown to the right of the curves</p></caption><graphic xlink:href="12885_2018_4147_Fig5_HTML" id="MO5"/></fig></p><p id="Par41">Similarly, an analysis of Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratio was performed to assess its influence on GBC patient survival. Kaplan-Meier survival analyses revealed that a&#x02009;&#x0003e;&#x02009;1 Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratio was associated with a significant shorter median survival than patients with a&#x02009;&#x02264;&#x02009;1 Foxp3<sup>+</sup>/CD8<sup>+</sup> T cell ratio (3.2 vs. 11.5&#x000a0;months, respectively; <italic>p</italic>&#x02009;=&#x02009;0.002) (Fig. <xref rid="Fig5" ref-type="fig">5d</xref>).</p></sec><sec id="Sec14"><title>CD8<sup>+</sup> T cell infiltration is a prognostic predictor for survival of gallbladder cancer patients</title><p id="Par42">Cox&#x02019;s proportional hazards model was used to analyze if the examined parameters could act as prognostic predictors for GBC patients. Only CD8<sup>+</sup> T cell infiltration was identified by Cox univariate regression as a significant prognostic biomarker (<italic>p</italic>&#x02009;=&#x02009;0.003; HR&#x02009;=&#x02009;0.24; CI&#x02009;=&#x02009;0.09&#x02013;0.62) (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S1). The multiparametric analysis of T cell infiltration respect to patient&#x02019;s demographic characteristics, histopathological findings, or clinic pathological features did not show significant correlations (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Table S2).</p></sec></sec><sec id="Sec15"><title>Discussion</title><p id="Par43">Tumor-infiltrating immune cells are representative of the tumor immune microenvironment and constitute an accepted manifestation of the host immune response against cancer. T cells are functionally heterogeneous and consist of various immune cell subgroups. Therefore, T cells can play dual roles, potentially either controlling or promoting malignancies. Generally, while CD8<sup>+</sup> T cell tumor infiltration is associated with favorable prognosis, a high prevalence of Foxp3<sup>+</sup> Tregs within the tumor microenvironment indicates a malignant phenotype and adverse outcome for different kinds of cancer [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. The immune system involvement in the pathogenesis and control of GBC has only been partially studied. The present work is one of the first to evaluate associations between the number of different TIL subtypes and the overall survival in a cohort of South American GBC patients at distinct disease stages.</p><p id="Par44">Likewise, a possible relationship between tumor-infiltrating immune cells and GBC prognosis was previously suggested by Nakakubo et al. [<xref ref-type="bibr" rid="CR29">29</xref>] in a pioneering study in which 45 tumor samples from GBC patients and 65 benign gallbladder tissues were examined. These authors reported an increased quantity of CD4<sup>+</sup>, CD8<sup>+</sup> and DCs in GBC samples, and their observations significantly correlated with prolonged patient survival. In turn, a report on 375 BTC patients, including 69 GBC samples, indicated that GBC patients with intraepithelial tumor-infiltrating CD4<sup>+</sup> and CD8<sup>+</sup> T cells showed significantly longer overall survival [<xref ref-type="bibr" rid="CR14">14</xref>]. However, no correlation was made between disease stage and infiltration by regulatory T cells in these studies. In a more recent study, Oguro et al. [<xref ref-type="bibr" rid="CR30">30</xref>] analyzed 211 GBC samples and found that a lower density of tumor-infiltrating CD8<sup>+</sup> cells and higher ratios between Foxp3<sup>+</sup>/CD4<sup>+</sup>, B and T lymphocyte attenuator/CD8<sup>+</sup>, and casitas-B-lineage lymphoma protein-b/CD8<sup>+</sup> were significantly associated with shorter overall survival in GBC patients. Nevertheless, the balance between pro-inflammatory CD8<sup>+</sup> tumor-infiltrating immune cell subpopulations and Foxp3<sup>+</sup> T cells, and their impact at different disease stages on GBC patient survival has not yet been established.</p><p id="Par45">Among our obtained results, a greater infiltration of CD8<sup>+</sup> T cells in cancer tissue was associated with a favorable prognostic biomarker particularly for advanced stage GBC patients. Additionally, the presence of Foxp3+ T cells correlated with poor survival outcome for early stage patients, suggesting that these cells may be regulatory T lymphocytes and may play a role in controlling the immune response towards GBC during the disease onset. However, although Foxp3 expression is generally considered a useful marker for Tregs, its transient expression in other T cells subpopulations make that a role for Foxp3<sup>+</sup> cells lacking Treg function, although improbable, may not be discarded.</p><p id="Par46">Moreover, our results also indicate that CD4<sup>+</sup> T cell infiltration is not associated with clinical outcomes in our GBC patient cohort. Although it is generally accepted that CD4<sup>+</sup> T cells may contribute to suppression of tumor growth via T<sub>H</sub>1 cytokine production [<xref ref-type="bibr" rid="CR18">18</xref>], a low CD4<sup>+</sup>/CD8<sup>+</sup> ratio has also been associated with a better prognosis for colorectal cancer patients [<xref ref-type="bibr" rid="CR31">31</xref>]. In that sense, our results showed that lower CD4<sup>+</sup>/CD8<sup>+</sup> and Foxp3<sup>+</sup>/CD8<sup>+</sup> ratios correlated with a better prognosis for all GBC patients, especially those in the advanced stages. This observation suggests that the presence of CD4<sup>+</sup> T cells is insufficient to contain tumor growth in a poor CD8<sup>+</sup> T cells environment, and that Foxp3+ T cells (probably Tregs) may adversely affect the ability of CD8<sup>+</sup> T cells to attack GBC tumors. According to protocols available at the time of surgery, only 10 patients included in this study received adjuvant treatment (chemotherapy, radiotherapy), as shown in Table <xref rid="Tab1" ref-type="table">1</xref>. However, considering that samples were obtained from surgical specimens before any treatment, the degree of immune cell infiltration found in the samples did not differ from the rest of the patients. In terms of survival, the statistical analyzes did not show any differences between the groups regarding the use of adjuvant therapies (data not shown).</p><p id="Par47">Few groups worldwide have researched the influence of tumor-infiltrating immune cells on GBC prognosis. Out of a total 5 studies, two were made with Japanese patients [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>], two with German patients [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR32">32</xref>], and one with Chinese patients [<xref ref-type="bibr" rid="CR33">33</xref>]. Chile has the highest GBC incidence and mortality rate among women worldwide [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. The most important risk factor in Chile is high gallstone prevalence and other inflammatory associated conditions caused by bacterial infections, which leads to chronic inflammation [<xref ref-type="bibr" rid="CR35">35</xref>]. This condition, present in all cases reported here, has not been described in any other studies and may contribute to some differences detected in infiltrating T cell subpopulations. The recurrent cycles of gallbladder epithelium damage and repair enable a chronic inflammatory environment that promotes progressive morphological impairment associated with carcinogenesis [<xref ref-type="bibr" rid="CR35">35</xref>], and probably with an early immune cell infiltration as well.</p><p id="Par48">In turn, a second inflammation-independent tumorigenesis process associated with anomalous pancreatobiliary duct junction is more frequent in Japan and China [<xref ref-type="bibr" rid="CR36">36</xref>]. A carcinogenesis process induced by inflammation may have a different early immune response than an inflammatory-independent tumorigenesis process, explaining some differences in our results compared to other previous studies. Additionally, GBC in Chile has been associated to the <italic>Mapuche</italic> ethnic group [<xref ref-type="bibr" rid="CR1">1</xref>]. Although, we failed to detect any correlation between GBC cohort and ethnicity, it is known that a great majority of the Chilean population bears more than 60% of Native American genes [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par49">Indeed, our results demonstrated that all tumors of Chilean patients were infiltrated by CD3<sup>+</sup> T cells, while only 30&#x02013;50% of the Japanese and German samples showed this kind of infiltration [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The discrepancy may be explained by the difference of origins and characteristics of patient cohorts, although differences in used criteria for positivity cannot be discarded. Furthermore, Nakakubo et al. [<xref ref-type="bibr" rid="CR29">29</xref>] and Goeppert et al. [<xref ref-type="bibr" rid="CR14">14</xref>] found that an increased quantity of total or intraepithelial CD4<sup>+</sup> T cells correlates with prolonged GBC patient survival. In contrast, the present work indicates that CD4<sup>+</sup> T cell infiltration, which is present in the majority of the samples, does not influence the survival of GBC patients. Differences in the GBC carcinogenesis pathways can lead to diverse anti-tumor immune responses, determining the nature of immune cell infiltration. Ultimately, these variances could impact GBC progression and overall patient survival.</p></sec><sec id="Sec16"><title>Conclusions</title><p id="Par50">In conclusion, the results of this study strongly indicate that a natural host CD8<sup>+</sup> T cell-mediated immune response against GBC increases patient survival. This finding could be useful in clinical decisions related to management and treatment of advanced GBC patients. Also, it encourages the design and development of adjuvant immunotherapeutic approaches against GBC. One of the most important findings of this study is that disease progression does not imply a loss of tumor immunogenicity, however, the kind of response and cell subtypes activated in tumor environment may define the response effect. In fact, immunological aspects observed in situ, particularly the presence of CD8<sup>+</sup> T cells or Foxp3<sup>+</sup> T cells, together with other histopathological characteristics, may permit identifying the group of patients that must be handled with a more aggressive strategy in accordance with the expected prognosis. In the future, this may facilitate the selection of candidates for immunotherapy approaches.</p><p id="Par51">Some immunotherapy trials against GBC use peptide-based vaccines or peptide-loaded DCs [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. These strategies have shown modest clinical improvements, likely due to induced tolerance by a dominant single tumor peptide or the selection of antigen-negative tumor cells. In contrast, a DC vaccine using autologous tumor cell lysates combined with adoptive T cell immunotherapy in patients with intrahepatic cholangiocarcinoma reported improved progression-free and overall survival [<xref ref-type="bibr" rid="CR40">40</xref>]. Autologous tumor cell lysates have also been tested as antigen providers for DCs in melanoma that induced a strong and more extensive immunological response against tumors [<xref ref-type="bibr" rid="CR41">41</xref>]. A useful and promising alternative is the preparation of allogeneic cancer cell lysates that have demonstrated to provide a standardized applicable source of tumor-specific antigens, also in patients with non-resectable tumors [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Particularly, allogeneic tumor cell lysates obtained from heat shocked conditioned tumor cells contain elevated levels of danger signals (like released HMGB1 and translocated calreticulin), which improve DC maturation and tumor antigen cross-presentation [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. In fact, clinical benefits reported by our group in the use of autologous DCs loaded with allogeneic conditioned tumor cell lysates in melanoma [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>] and prostate cancer [<xref ref-type="bibr" rid="CR9">9</xref>], encouraged us to explore the use of allogeneic conditioned GBC lysates-loaded DCs in future clinical trials. Finally, considering that Chilean GBC patients are infiltrated by T cells, immune checkpoint therapies such as blocking of PD-1 or CTLA4, along or in combination with DC vaccines could be a reasonable strategy for the treatment of GBC.</p></sec><sec sec-type="supplementary-material"><title>Additional file</title><sec id="Sec17"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12885_2018_4147_MOESM1_ESM.doc"><label>Additional file 1:</label><caption><p><bold>Table S1.</bold> Survival prognostic factors in Gallbladder cancer patients. Cox&#x02019;s proportion. <bold>Table S2.</bold> CD3<sup>+</sup>, CD8<sup>+</sup> and Foxp3<sup>+</sup> T cell infiltration related to patient&#x02019;s demographic characteristics. <bold>Figure S1.</bold> Overall survival of gallbladder cancer patients. Kaplan-Meier survival curves for GBC patients stratified according to the disease stage. <bold>Figure S2.</bold> CD4<sup>+</sup> T cell infiltration in gallbladder cancer tissues does not correlates with patient survival. (DOC 264&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BTC</term><def><p id="Par5">Biliary tract cancer</p></def></def-item><def-item><term>CD</term><def><p id="Par6">Cluster of differentiation</p></def></def-item><def-item><term>CI</term><def><p id="Par7">Confidence interval</p></def></def-item><def-item><term>CTLA4</term><def><p id="Par8">Cytotoxic T-lymphocyte antigen 4</p></def></def-item><def-item><term>DC</term><def><p id="Par9">Dendritic cells</p></def></def-item><def-item><term>Foxp3</term><def><p id="Par10">Forkhead box P3</p></def></def-item><def-item><term>GBC</term><def><p id="Par11">GBC</p></def></def-item><def-item><term>HMGB1</term><def><p id="Par12">High mobility group box-1</p></def></def-item><def-item><term>HR</term><def><p id="Par13">Hazard ratio</p></def></def-item><def-item><term>IgG</term><def><p id="Par14">Immunoglobulin G</p></def></def-item><def-item><term>IL</term><def><p id="Par15">Interleukin</p></def></def-item><def-item><term>MHC</term><def><p id="Par16">Major histocompatibility complex</p></def></def-item><def-item><term>PD1</term><def><p id="Par17">Programmed cell death protein-1</p></def></def-item><def-item><term>TGF</term><def><p id="Par18">Transforming growth factor</p></def></def-item><def-item><term>TIL</term><def><p id="Par19">Tumor-infiltrating lymphocytes</p></def></def-item><def-item><term>Treg</term><def><p id="Par20">Regulatory T cells</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12885-018-4147-6) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Dr. Benedict Chambers for critical reading and English editing of the manuscript.</p><sec id="FPar1"><title>Funding</title><p id="Par52">This work was supported by grants from the National Fund for Scientific and Technological Development (FONDECYT) 1171213 (FSO) and 11160380 (AT); the Fund for the Promotion of Scientific and Technological Development (FONDEF) ID16i10148 (FSO and ML); Millennium Institute on Immunology and Immunotherapy (MIII) P09/016-F (FSO, AT and ML); National Commission for Scientific and Technological Research (CONICYT)-PCHA/Doctorado Nacional/21130465 (DRS); CONICYT-PAI/TESIS DOCTORADO SECTOR PRODUCTIVO/7815110008 (DRS); FONDECYT POSTDOCTORADO 3170917(MAG). All the funding bodies supported the acquisition for all the required material for experiments and analysis, besides stipend for authors.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par53">The datasets and materials used and analyzed during the current study are available from the corresponding author upon reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>PF, DRS, and MAG performed the IHC of the tumor samples; PF, FC, and MU obtained the patient&#x02019;s samples; PV, LT, and MTR performed the histological examination of the tumor samples; PF, DRS, AT, MAG, ML, and FSO analyzed and interpreted the patient data; PF, DRS, AT, and FSO wrote the paper. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par54">The study was performed in agreement with the Helsinki Declaration and approved by the Bioethical Committee for Human Research of the Faculty of Medicine, University of Chile (ID number: 078&#x02013;2008). All patients signed a letter of informed consent to participate at the time of surgery.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par55">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par56">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par57">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hundal</surname><given-names>R</given-names></name><name><surname>Shaffer</surname><given-names>EA</given-names></name></person-group><article-title>Gallbladder cancer: epidemiology and outcome</article-title><source>Clin Epidemiol</source><year>2014</year><volume>6</volume><fpage>99</fpage><lpage>109</lpage><?supplied-pmid 24634588?><pub-id pub-id-type="pmid">24634588</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Dikshit</surname><given-names>R</given-names></name><name><surname>Eser</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Rebelo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</article-title><source>Int J Cancer</source><year>2015</year><volume>136</volume><fpage>E359</fpage><lpage>E386</lpage><pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id><?supplied-pmid 25220842?><pub-id pub-id-type="pmid">25220842</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roa</surname><given-names>I</given-names></name><name><surname>Ibacache</surname><given-names>G</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>S</given-names></name><name><surname>de Aretxabala</surname><given-names>X</given-names></name></person-group><article-title>Gallbladder cancer in Chile: pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases</article-title><source>Am J Clin Pathol</source><year>2014</year><volume>141</volume><fpage>675</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1309/AJCPQT3ELN2BBCKA</pub-id><?supplied-pmid 24713738?><pub-id pub-id-type="pmid">24713738</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roa</surname><given-names>I</given-names></name><name><surname>de Aretxabala</surname><given-names>X</given-names></name></person-group><article-title>Gallbladder cancer in Chile: what have we learned?</article-title><source>Curr Opin Gastroenterol</source><year>2015</year><volume>31</volume><fpage>269</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1097/MOG.0000000000000164</pub-id><?supplied-pmid 25693005?><pub-id pub-id-type="pmid">25693005</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smok</surname><given-names>G</given-names></name><name><surname>Cervilla</surname><given-names>K</given-names></name></person-group><article-title>Carcinoma of the gallbladder: analysis of 373 cases</article-title><source>Rev Med Chil</source><year>1986</year><volume>114</volume><fpage>1040</fpage><lpage>1046</lpage><?supplied-pmid 3602679?><pub-id pub-id-type="pmid">3602679</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheth</surname><given-names>S</given-names></name><name><surname>Bedford</surname><given-names>A</given-names></name><name><surname>Chopra</surname><given-names>S</given-names></name></person-group><article-title>Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy</article-title><source>Am J Gastroenterol</source><year>2000</year><volume>95</volume><fpage>1402</fpage><lpage>1410</lpage><pub-id pub-id-type="doi">10.1111/j.1572-0241.2000.02070.x</pub-id><?supplied-pmid 10894571?><pub-id pub-id-type="pmid">10894571</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez</surname><given-names>MN</given-names></name><name><surname>Pereda</surname><given-names>C</given-names></name><name><surname>Segal</surname><given-names>G</given-names></name><name><surname>Mu&#x000f1;oz</surname><given-names>L</given-names></name><name><surname>Aguilera</surname><given-names>R</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>FE</given-names></name><etal/></person-group><article-title>Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor &#x003b2;-expressing T cells</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>945</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.18.0794</pub-id><?supplied-pmid 19139436?><pub-id pub-id-type="pmid">19139436</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilera</surname><given-names>R</given-names></name><name><surname>Saffie</surname><given-names>C</given-names></name><name><surname>Tittarelli</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>FE</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>M</given-names></name><name><surname>Reyes</surname><given-names>D</given-names></name><etal/></person-group><article-title>Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells</article-title><source>Clin Cancer Res</source><year>2011</year><volume>17</volume><fpage>2474</fpage><lpage>2483</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2384</pub-id><?supplied-pmid 21292818?><pub-id pub-id-type="pmid">21292818</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reyes</surname><given-names>D</given-names></name><name><surname>Salazar</surname><given-names>L</given-names></name><name><surname>Espinoza</surname><given-names>E</given-names></name><name><surname>Pereda</surname><given-names>C</given-names></name><name><surname>Castell&#x000f3;n</surname><given-names>E</given-names></name><name><surname>Valdevenito</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients</article-title><source>Br J Cancer</source><year>2013</year><volume>109</volume><fpage>1488</fpage><lpage>1497</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.494</pub-id><?supplied-pmid 23989944?><pub-id pub-id-type="pmid">23989944</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J</given-names></name><name><surname>Costes</surname><given-names>A</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F</given-names></name><name><surname>Kirilovsky</surname><given-names>A</given-names></name><name><surname>Mlecnik</surname><given-names>B</given-names></name><name><surname>Lagorce-Pag&#x000e8;s</surname><given-names>C</given-names></name><etal/></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id><?supplied-pmid 17008531?><pub-id pub-id-type="pmid">17008531</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Conejo-Garcia</surname><given-names>JR</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Gimotty</surname><given-names>PA</given-names></name><name><surname>Massobrio</surname><given-names>M</given-names></name><name><surname>Regnani</surname><given-names>G</given-names></name><etal/></person-group><article-title>Intratumoural T cells, recurrence, and survival in epithelial ovarian cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>348</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020177</pub-id><?supplied-pmid 12529460?><pub-id pub-id-type="pmid">12529460</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmoud</surname><given-names>SM</given-names></name><name><surname>Paish</surname><given-names>EC</given-names></name><name><surname>Powe</surname><given-names>DG</given-names></name><name><surname>Macmillan</surname><given-names>RD</given-names></name><name><surname>Grainge</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><fpage>1949</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.30.5037</pub-id><?supplied-pmid 21483002?><pub-id pub-id-type="pmid">21483002</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryschich</surname><given-names>E</given-names></name><name><surname>N&#x000f6;tzel</surname><given-names>T</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><name><surname>Autschbach</surname><given-names>F</given-names></name><name><surname>Ferguson</surname><given-names>J</given-names></name><name><surname>Simon</surname><given-names>I</given-names></name><etal/></person-group><article-title>Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>498</fpage><lpage>504</lpage><?supplied-pmid 15701833?><pub-id pub-id-type="pmid">15701833</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goeppert</surname><given-names>B</given-names></name><name><surname>Frauenschuh</surname><given-names>L</given-names></name><name><surname>Zucknick</surname><given-names>M</given-names></name><name><surname>Stenzinger</surname><given-names>A</given-names></name><name><surname>Andrulis</surname><given-names>M</given-names></name><name><surname>Klauschen</surname><given-names>F</given-names></name><etal/></person-group><article-title>Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer</article-title><source>Br J Cancer</source><year>2013</year><volume>109</volume><fpage>2665</fpage><lpage>2674</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.610</pub-id><?supplied-pmid 24136146?><pub-id pub-id-type="pmid">24136146</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sznurkowski</surname><given-names>JJ</given-names></name><name><surname>Zawrocki</surname><given-names>A</given-names></name><name><surname>Emerich</surname><given-names>J</given-names></name><name><surname>Biernat</surname><given-names>W</given-names></name></person-group><article-title>Prognostic significance of CD4+ and CD8+ T cell infiltration within cancer cell nests in vulvar squamous cell carcinoma</article-title><source>Int J Gynecol Cancer</source><year>2011</year><volume>21</volume><fpage>717</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1097/IGC.0b013e3182131f36</pub-id><?supplied-pmid 21543933?><pub-id pub-id-type="pmid">21543933</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bie&#x00144;kowski</surname><given-names>M</given-names></name><name><surname>Preusser</surname><given-names>M</given-names></name></person-group><article-title>Prognostic role of tumor-infiltrating inflammatory cells in brain tumors: literature review</article-title><source>Curr Opin Neurol</source><year>2015</year><volume>28</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1097/WCO.0000000000000251</pub-id><?supplied-pmid 26402405?><pub-id pub-id-type="pmid">26402405</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mumberg</surname><given-names>D</given-names></name><name><surname>Monach</surname><given-names>PA</given-names></name><name><surname>Wanderling</surname><given-names>S</given-names></name><name><surname>Philip</surname><given-names>M</given-names></name><name><surname>Toledano</surname><given-names>AY</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name></person-group><article-title>Schreiber H. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma</article-title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>8633</fpage><lpage>8638</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.15.8633</pub-id><?supplied-pmid 10411927?><pub-id pub-id-type="pmid">10411927</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beatty</surname><given-names>G</given-names></name><name><surname>Paterson</surname><given-names>Y</given-names></name></person-group><article-title>IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma</article-title><source>J Immunol</source><year>2001</year><volume>166</volume><fpage>2276</fpage><lpage>2282</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.166.4.2276</pub-id><?supplied-pmid 11160282?><pub-id pub-id-type="pmid">11160282</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>RF</given-names></name></person-group><article-title>Regulatory T cells and cancer</article-title><source>Curr Opin Immunol</source><year>2007</year><volume>19</volume><fpage>217</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2007.02.004</pub-id><?supplied-pmid 17306521?><pub-id pub-id-type="pmid">17306521</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hori</surname><given-names>S</given-names></name><name><surname>Nomura</surname><given-names>T</given-names></name><name><surname>Sakaguchi</surname><given-names>S</given-names></name></person-group><article-title>Control of regulatory T cell development by the transcription factor Foxp3</article-title><source>Science</source><year>2003</year><volume>299</volume><fpage>1057</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1126/science.1079490</pub-id><?supplied-pmid 12522256?><pub-id pub-id-type="pmid">12522256</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Rudensky</surname><given-names>AY</given-names></name></person-group><article-title>Treg cells in cancer: a case of multiple personality disorder</article-title><source>Sci Transl Med</source><year>2012</year><volume>4</volume><fpage>164fs44</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3005283</pub-id><?supplied-pmid 23241741?><pub-id pub-id-type="pmid">23241741</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabenbauer</surname><given-names>GG</given-names></name><name><surname>Lahmer</surname><given-names>G</given-names></name><name><surname>Distel</surname><given-names>L</given-names></name><name><surname>Niedobitek</surname><given-names>G</given-names></name></person-group><article-title>Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>3355</fpage><lpage>3360</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2434</pub-id><?supplied-pmid 16740757?><pub-id pub-id-type="pmid">16740757</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>RL</given-names></name><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name></person-group><article-title>Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer</article-title><source>J Cancer Res Clin Oncol</source><year>2010</year><volume>136</volume><fpage>1585</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1007/s00432-010-0816-9</pub-id><?supplied-pmid 20221835?><pub-id pub-id-type="pmid">20221835</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathai</surname><given-names>AM</given-names></name><name><surname>Kapadia</surname><given-names>MJ</given-names></name><name><surname>Alexander</surname><given-names>J</given-names></name><name><surname>Kernochan</surname><given-names>LE</given-names></name><name><surname>Swanson</surname><given-names>PE</given-names></name><name><surname>Yeh</surname><given-names>MM</given-names></name></person-group><article-title>Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma</article-title><source>Am J Surg Pathol</source><year>2012</year><volume>36</volume><fpage>980</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1097/PAS.0b013e31824e9b7c</pub-id><?supplied-pmid 22446942?><pub-id pub-id-type="pmid">22446942</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oshikiri</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Shichinohe</surname><given-names>T</given-names></name><name><surname>Suzuoki</surname><given-names>M</given-names></name><name><surname>Hiraoka</surname><given-names>K</given-names></name><name><surname>Nakakubo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response</article-title><source>J Surg Oncol</source><year>2003</year><volume>84</volume><fpage>224</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1002/jso.10321</pub-id><?supplied-pmid 14756433?><pub-id pub-id-type="pmid">14756433</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takagi</surname><given-names>S</given-names></name><name><surname>Miyagawa</surname><given-names>S</given-names></name><name><surname>Ichikawa</surname><given-names>E</given-names></name><name><surname>Soeda</surname><given-names>J</given-names></name><name><surname>Miwa</surname><given-names>S</given-names></name><name><surname>Miyagawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Dendritic cells, T-cell infiltration, and Grp94 expression in cholangiocellular carcinoma</article-title><source>Hum Pathol</source><year>2004</year><volume>35</volume><fpage>881</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1016/j.humpath.2004.03.016</pub-id><?supplied-pmid 15257553?><pub-id pub-id-type="pmid">15257553</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiraoka</surname><given-names>N</given-names></name><name><surname>Onozato</surname><given-names>K</given-names></name><name><surname>Kosuge</surname><given-names>T</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>5423</fpage><lpage>5434</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-0369</pub-id><?supplied-pmid 17000676?><pub-id pub-id-type="pmid">17000676</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ino</surname><given-names>Y</given-names></name><name><surname>Yamazaki-Itoh</surname><given-names>R</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Kosuge</surname><given-names>T</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Hiraoka</surname><given-names>N</given-names></name></person-group><article-title>Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer</article-title><source>Br J Cancer</source><year>2013</year><volume>108</volume><fpage>914</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1038/bjc.2013.32</pub-id><?supplied-pmid 23385730?><pub-id pub-id-type="pmid">23385730</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakakubo</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>Y</given-names></name><name><surname>Hida</surname><given-names>Y</given-names></name><name><surname>Oshikiri</surname><given-names>T</given-names></name><name><surname>Suzuoki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical significance of immune cell infiltration within gallbladder cancer</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><fpage>1736</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6601331</pub-id><?supplied-pmid 14583778?><pub-id pub-id-type="pmid">14583778</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oguro</surname><given-names>S</given-names></name><name><surname>Ino</surname><given-names>Y</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Hatanaka</surname><given-names>Y</given-names></name><name><surname>Matsuno</surname><given-names>Y</given-names></name><name><surname>Esaki</surname><given-names>M</given-names></name><etal/></person-group><article-title>Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer</article-title><source>Cancer Sci</source><year>2015</year><volume>106</volume><fpage>1750</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1111/cas.12825</pub-id><?supplied-pmid 26395180?><pub-id pub-id-type="pmid">26395180</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diederichsen</surname><given-names>AC</given-names></name><name><surname>Hjelmborg</surname><given-names>JV</given-names></name><name><surname>Christensen</surname><given-names>PB</given-names></name><name><surname>Zeuthen</surname><given-names>J</given-names></name><name><surname>Fenger</surname><given-names>C</given-names></name></person-group><article-title>Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells</article-title><source>Cancer Immunol Immunother</source><year>2003</year><volume>52</volume><fpage>423</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1007/s00262-003-0388-5</pub-id><?supplied-pmid 12695859?><pub-id pub-id-type="pmid">12695859</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goeppert</surname><given-names>B</given-names></name><name><surname>Frauenschuh</surname><given-names>L</given-names></name><name><surname>Zucknick</surname><given-names>M</given-names></name><name><surname>Roessler</surname><given-names>S</given-names></name><name><surname>Mehrabi</surname><given-names>A</given-names></name><name><surname>Hafezi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer</article-title><source>Br J Cancer</source><year>2015</year><volume>113</volume><fpage>1343</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.337</pub-id><?supplied-pmid 26461054?><pub-id pub-id-type="pmid">26461054</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>M</given-names></name></person-group><article-title>Tumour-infiltrating Foxp3+ and IL-17-producing T cells affect the progression and prognosis of gallbladder carcinoma after surgery</article-title><source>Scand J Immunol</source><year>2013</year><volume>78</volume><fpage>516</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1111/sji.12109</pub-id><?supplied-pmid 24007242?><pub-id pub-id-type="pmid">24007242</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randi</surname><given-names>G</given-names></name><name><surname>Malvezzi</surname><given-names>M</given-names></name><name><surname>Levi</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name></person-group><article-title>Epidemiology of biliary tract cancers: an update</article-title><source>Ann Oncol</source><year>2009</year><volume>20</volume><fpage>146</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdn533</pub-id><?supplied-pmid 18667395?><pub-id pub-id-type="pmid">18667395</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Espinoza</surname><given-names>JA</given-names></name><name><surname>Bizama</surname><given-names>C</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>P</given-names></name><name><surname>Ferreccio</surname><given-names>C</given-names></name><name><surname>Javle</surname><given-names>M</given-names></name><name><surname>Miquel</surname><given-names>JF</given-names></name><etal/></person-group><article-title>The inflammatory inception of gallbladder cancer</article-title><source>Biochim Biophys Acta</source><year>2016</year><volume>1865</volume><fpage>245</fpage><lpage>254</lpage><?supplied-pmid 26980625?><pub-id pub-id-type="pmid">26980625</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wistuba</surname><given-names>II</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name></person-group><article-title>Gallbladder cancer: lessons from a rare tumour</article-title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><fpage>695</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/nrc1429</pub-id><?supplied-pmid 15343276?><pub-id pub-id-type="pmid">15343276</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>M</given-names></name><name><surname>Pulgar</surname><given-names>I</given-names></name><name><surname>Gallo</surname><given-names>C</given-names></name><name><surname>Bortolini</surname><given-names>MC</given-names></name><name><surname>Canizales-Quinteros</surname><given-names>S</given-names></name><name><surname>Bedoya</surname><given-names>G</given-names></name><etal/></person-group><article-title>Gene geography of Chile: regional distribution of American, European and African genetic contributions</article-title><source>Rev Med Chil</source><year>2014</year><volume>142</volume><fpage>281</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.4067/S0034-98872014000300001</pub-id><?supplied-pmid 25052264?><pub-id pub-id-type="pmid">25052264</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>EI</given-names></name><name><surname>Yee</surname><given-names>NS</given-names></name></person-group><article-title>Molecular genetics and targeted therapeutics in biliary tract carcinoma</article-title><source>World J Gastroenterol</source><year>2016</year><volume>22</volume><fpage>1335</fpage><lpage>1347</lpage><pub-id pub-id-type="doi">10.3748/wjg.v22.i4.1335</pub-id><?supplied-pmid 26819503?><pub-id pub-id-type="pmid">26819503</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chai</surname><given-names>Y</given-names></name></person-group><article-title>Immunotherapy of biliary tract cancer</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>2817</fpage><lpage>2821</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4743-x</pub-id><?supplied-pmid 26729196?><pub-id pub-id-type="pmid">26729196</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Kotera</surname><given-names>Y</given-names></name><name><surname>Aruga</surname><given-names>A</given-names></name><name><surname>Takeshita</surname><given-names>N</given-names></name><name><surname>Takasaki</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><article-title>Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma</article-title><source>J Hepatobiliary Pancreat Sci</source><year>2012</year><volume>19</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1007/s00534-011-0437-y</pub-id><?supplied-pmid 21874278?><pub-id pub-id-type="pmid">21874278</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engell-Noerregaard</surname><given-names>L</given-names></name><name><surname>Hansen</surname><given-names>TH</given-names></name><name><surname>Andersen</surname><given-names>MH</given-names></name><name><surname>Thor Straten</surname><given-names>P</given-names></name><name><surname>Svane</surname><given-names>IM</given-names></name></person-group><article-title>Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0568-4</pub-id><?supplied-pmid 18719915?><pub-id pub-id-type="pmid">18719915</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;ltl</surname><given-names>L</given-names></name><name><surname>Ramoner</surname><given-names>R</given-names></name><name><surname>Zelle-Rieser</surname><given-names>C</given-names></name><name><surname>Gander</surname><given-names>H</given-names></name><name><surname>Putz</surname><given-names>T</given-names></name><name><surname>Papesh</surname><given-names>C</given-names></name><etal/></person-group><article-title>Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide</article-title><source>Cancer Immunol Immunother</source><year>2005</year><volume>54</volume><fpage>663</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1007/s00262-004-0629-2</pub-id><?supplied-pmid 15918076?><pub-id pub-id-type="pmid">15918076</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>CL</given-names></name><name><surname>Coukos</surname><given-names>G</given-names></name><name><surname>Kandalaft</surname><given-names>LE</given-names></name></person-group><article-title>Whole tumor antigen vaccines: where are we?</article-title><source>Vaccines (Basel)</source><year>2015</year><volume>3</volume><fpage>344</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020344</pub-id><pub-id pub-id-type="pmid">26343191</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skitzki</surname><given-names>JJ</given-names></name><name><surname>Repasky</surname><given-names>EA</given-names></name><name><surname>Evans</surname><given-names>EE</given-names></name></person-group><article-title>Hyperthermia as an immunotherapy strategy for cancer</article-title><source>Curr Opin Investig Drugs</source><year>2009</year><volume>10</volume><fpage>550</fpage><lpage>558</lpage><?supplied-pmid 19513944?><pub-id pub-id-type="pmid">19513944</pub-id></element-citation></ref></ref-list></back></article>